| Name | Title | Contact Details |
|---|---|---|
Wendy Vargas |
VP Global CO Project Leader Head, Rare Disease, Rare Blood Disorders, Oncology | Profile |
Sophie Forge |
VP - Global Head of Digital R&D Pipeline and Project analytics | Profile |
Andrey Malyy |
Global Head of Information Technology Solutions, Innovation, CX and Mobile | Profile |
Arnaud Robert |
Executive Vice President and Chief Digital Officer | Profile |
Michael Shanno |
Head of Digital and Information Technology | Profile |
AzoRx, Inc. is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LifeTek Solutions is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TYRX is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sun Pharma is the world`s fourth largest specialty generic pharmaceutical company and India`s top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma`s global presence is supported by 50 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues.
RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers.